About: Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Metastatic renal cell carcinoma (mRCC) is tumor resistant to all cytotoxic agents. During the last decade, effective targeted therapies emerged including sunitinib, pazopanib and the combination of bevacizumab with IFN-alfa. The use of bevacizumab plus IFN-alfa combination in mRCC is supported by the AVOREN trial. Although the primary end point of the AVOREN trial was overall survival, progression-free survival was used to evaluate efficacy and served as the basis of regulatory submission owing to the advent of targeted agents that probably resulted in the prolongation of overall survival in both experimental and control arms. The doubling of median progression-free survival in the AVOREN trials (from 5.4 to 10.2 months) is remarkably similar compared with the results of Phase III trials with sunitinib and pazopanib. Bevacizumab plus IFN-alfa is the only combined regimen currently used in mRCC and serves as a comparator in the trials combining bevacizumab with other agents.
  • Metastatic renal cell carcinoma (mRCC) is tumor resistant to all cytotoxic agents. During the last decade, effective targeted therapies emerged including sunitinib, pazopanib and the combination of bevacizumab with IFN-alfa. The use of bevacizumab plus IFN-alfa combination in mRCC is supported by the AVOREN trial. Although the primary end point of the AVOREN trial was overall survival, progression-free survival was used to evaluate efficacy and served as the basis of regulatory submission owing to the advent of targeted agents that probably resulted in the prolongation of overall survival in both experimental and control arms. The doubling of median progression-free survival in the AVOREN trials (from 5.4 to 10.2 months) is remarkably similar compared with the results of Phase III trials with sunitinib and pazopanib. Bevacizumab plus IFN-alfa is the only combined regimen currently used in mRCC and serves as a comparator in the trials combining bevacizumab with other agents. (en)
Title
  • Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.
  • Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial. (en)
skos:prefLabel
  • Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.
  • Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial. (en)
skos:notation
  • RIV/61989592:15110/12:33140649!RIV13-MSM-15110___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I
http://linked.open...iv/cisloPeriodika
  • 10
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 124789
http://linked.open...ai/riv/idVysledku
  • RIV/61989592:15110/12:33140649
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • renal cell carcinoma; bevacizumab (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV
  • [A9E595DD1D3E]
http://linked.open...i/riv/nazevZdroje
  • Expert Review of Anticancer Therapy
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 12
http://linked.open...iv/tvurceVysledku
  • Melichar, Bohuslav
  • Procházková, Hana
  • Vitásková, Denisa
issn
  • 1473-7140
number of pages
http://bibframe.org/vocab/doi
  • 10.1586/era.12.103
http://localhost/t...ganizacniJednotka
  • 15110
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 77 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software